The latest wave of pharma layoffs – at Moderna, at Biogen, at Johnson & Johnson and beyond – reflects the financial pressures reshaping the industry. Cuts have impacted digital departments, R&D, corporate headquarters, market access, and medical functions. And the cuts have been significant, often reflecting 20-40% of the workforce in specific areas.

These layoffs reflect two distinct forces shaping the pharmaceutical sector. On one hand, companies must adjust to natural business cycles – products lose exclusivity, some assets fail clinical trials and research programs are shut down when data doesn’t support continued investment. These are predictable risks inherent to the industry. On the other hand, companies are also responding to growing regulatory uncertainty and shifting reimbursement landscapes, which heighten financial pressures in ways that are harder to anticipate.

While layoffs may reflect difficult but necessary business decisions, how they’re executed and where companies choose to cut can have long-term consequences.